Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low.

Du D, Goldsmith J, Aikin KJ, Encinosa WE, Nardinelli C.

Health Aff (Millwood). 2012 May;31(5):1022-9. doi: 10.1377/hlthaff.2010.1004.

2.

Adverse drug event reporting.

Vaughan W.

Health Aff (Millwood). 2012 Aug;31(8):1911. doi: 10.1377/hlthaff.2012.0719. No abstract available.

3.

The educational potential of direct-to-consumer prescription drug advertising.

Kaphingst KA, DeJong W.

Health Aff (Millwood). 2004 Jul-Aug;23(4):143-50.

4.

Effects of comparative claims in prescription drug direct-to-consumer advertising on consumer perceptions and recall.

O'Donoghue AC, Williams PA, Sullivan HW, Boudewyns V, Squire C, Willoughby JF.

Soc Sci Med. 2014 Nov;120:1-11. doi: 10.1016/j.socscimed.2014.08.039. Epub 2014 Aug 28.

PMID:
25194471
5.

Ensuring that consumers receive appropriate information from drug ads: what is the FDA's role?

Waxman HA.

Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-256-8.

6.

Regulation of prescription drug promotion: direct-to-consumer advertising.

Baylor-Henry M, Drezin NA.

Clin Ther. 1998;20 Suppl C:C86-95. Review.

PMID:
9915094
7.

To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.

Schwartz MI.

Food Drug Law J. 2008;63(1):1-33. No abstract available.

PMID:
18561453
8.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

9.

Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.

Roberto G, Piccinni C, D'Alessandro R, Poluzzi E.

Cephalalgia. 2014 Jan;34(1):5-13. doi: 10.1177/0333102413499649. Epub 2013 Aug 6.

PMID:
23921799
11.

Changing effects of direct-to-consumer broadcast drug advertising information sources on prescription drug requests.

Lee AL.

Health Commun. 2009 Jun;24(4):361-76. doi: 10.1080/10410230902889480.

PMID:
19499430
12.

New DTCA Guidance--Enough to Empower Consumers?

Robertson CT.

N Engl J Med. 2015 Sep 17;373(12):1085-7. doi: 10.1056/NEJMp1508548. Epub 2015 Aug 19. No abstract available.

13.

Direct-to-consumer advertising of prescription drugs.

Frosch DL, Grande D.

LDI Issue Brief. 2010 Mar-Apr;15(3):1-4.

PMID:
20469541
14.
15.

Examining the FDA's oversight of direct-to-consumer advertising.

Gahart MT, Duhamel LM, Dievler A, Price R.

Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3-120-3.

16.

The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.

Greene JA, Watkins ES.

N Engl J Med. 2015 Sep 17;373(12):1087-9. doi: 10.1056/NEJMp1507924. Epub 2015 Aug 19. No abstract available.

17.

FDA direct-to-consumer advertising for prescription drugs: what are consumer preferences and response tendencies?

Khanfar N, Loudon D, Sircar-Ramsewak F.

Health Mark Q. 2007;24(1-2):77-91. doi: 10.1080/07359680802125899.

PMID:
19042521
18.

The federal regulation of prescription drug advertising and promotion.

Kessler DA, Pines WL.

JAMA. 1990 Nov 14;264(18):2409-15.

PMID:
2231998
19.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

20.

Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis.

Tippett EC, Chen BK.

Drug Saf. 2015 Dec;38(12):1169-78. doi: 10.1007/s40264-015-0340-6.

PMID:
26384489

Supplemental Content

Support Center